Sarepta Therapeutics said Friday that the deaths of two patients taking its marketed gene therapy Elevidys® (delandistrogene ...

Citi raised the firm’s price target on Sarepta (SRPT) to $14 from $12 and keeps a Sell rating on the shares. The company’s Q2 sales beat estimates ...

This regulatory relief, combined with several other compelling catalysts, creates a pathway for the stock to potentially ...

Although the revenue and EPS for Sarepta Therapeutics (SRPT) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with ...

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Sarepta Therapeutics now trades at book value with strong cash and cost-cutting plans, while ELEVIDYS may regain broader use.

The July CPI is expected to show a rise in annual retail inflation. AMC and Cisco among those reporting earnings. Nvidia ...

Fintel reports that on July 29, 2025, Oppenheimer upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) from ...

Vinay Prasad is returning to his role overseeing vaccine, gene therapy and blood product regulation at the U.S. Food and Drug ...

We recently published 11 Stocks That Jim Cramer Recently Talked About. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is one of the ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Analysts expect Sarepta Therapeutics to report an earnings per share (EPS) of $1.01. The announcement from Sarepta ...